-+ 0.00%
-+ 0.00%
-+ 0.00%

VERAXA Biotech to Merge With Voyager In $1.3B Business Combination, Launching Nasdaq-Listed Oncology Company

Benzinga·04/23/2025 05:51:38
Listen to the news
  • VERAXA's Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE") Candidates, with Strong and Differentiated Clinical Profiles
  • Company Pursuing Multiple Strategic Partnerships and Licensing Opportunities in 2025 and 2026
  • Transaction Values VERAXA at a Pre-money Equity Value of $1.3 Billion
  • Actively Working with Existing and New VERAXA Investors to Raise a Crossover Financing Round, which is Expected to Close Ahead of the Business Combination, Alongside up to $253 Million in Cash Held in Trust
  • Business Combination is Expected to be Completed in the Fourth Quarter of 2025
  • A Joint Investor Presentation Providing an Overview of the Proposed Transaction can be Viewed: https://dealroadshow.com/e/VER2025